Multimodal image-guided surgical and photodynamic interventions in head and neck cancer: From primary tumor to metastatic drainage

Clinical Cancer Research

Volumn 22, Issue 4, 2016, Pages 961-970

  Muhanna, Nidal ^a,b   Cui, Liyang ^a,c,d   Chan, Harley ^a,b   Burgess, Laura ^a,c   Jin, Cheng S ^a,b,e   MacDonald, Thomas D ^a,b   Huynh, Elizabeth ^a,c   Wang, Fan ^d   Chen, Juan ^a   Irish, Jonathan C ^a,b   Zheng, Gang ^a,b,c,e  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d PEKING UNIVERSITY   (China)

^e UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; COPPER 64; PORPHYRIN DERIVATIVE; PORPHYRIN LIPOPROTEIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CHOLESTEROL ESTER; CHOLESTEROL OLEATE; DIMYRISTOYLPHOSPHATIDYLCHOLINE; NANOPARTICLE; PHOTOSENSITIZING AGENT; PORPHYRIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER SURGERY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; FLUORESCENCE IMAGING; HEAD AND NECK CANCER; INTRAOPERATIVE PERIOD; LYMPH NODE METASTASIS; LYMPHATIC DRAINAGE; MOUSE; MOUTH SQUAMOUS CELL CARCINOMA; MULTIMODALITY CANCER THERAPY; NONHUMAN; PHOTODYNAMIC THERAPY; POSITRON EMISSION TOMOGRAPHY; PREOPERATIVE EVALUATION; PRIMARY TUMOR; PRIORITY JOURNAL; RABBIT MODEL; SIGNAL DETECTION; TUMOR RECURRENCE; ANIMAL; CARCINOMA, SQUAMOUS CELL; COMPUTER ASSISTED SURGERY; DRUG SCREENING; HEAD AND NECK NEOPLASMS; HUMAN; PATHOLOGY; PHOTOCHEMOTHERAPY; RABBIT; SECONDARY; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CHOLESTEROL ESTERS; COMBINED MODALITY THERAPY; DIMYRISTOYLPHOSPHATIDYLCHOLINE; HEAD AND NECK NEOPLASMS; HUMANS; LYMPHATIC METASTASIS; NANOPARTICLES; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PORPHYRINS; RABBITS; SURGERY, COMPUTER-ASSISTED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84964199216     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-15-1235     Document Type: Article

References (40)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
2. Argiris A, Karamouzis MV, RabenD, Ferris RL. Head and neck cancer. Lancet 2008;371:1695-709.
3. Blot WJ, McLaughlin JK, Winn DM, Austin DF, Greenberg RS, Preston- Martin S, et al. Smoking and drinking in relation to oral and pharyngeal cancer. Cancer Res 1988;48:3282-7.
4. Boffetta P, Hecht S, Gray N, Gupta P, Straif K. Smokeless tobacco and cancer. Lancet Oncol 2008;9:667-75.
5. Gandini S, Botteri E, Iodice S, Boniol M, Lowenfels AB, Maisonneuve P, et al. Tobacco smoking and cancer: a meta-analysis. Int J Cancer 2008; 122:155-64.
6. Hashibe M, Boffetta P, Zaridze D, Shangina O, Szeszenia-Dabrowska N, Mates D, et al. Evidence for an important role of alcohol- and aldehydemetabolizing genes in cancers of the upper aerodigestive tract. Cancer Epidemiol Biomarkers Prev 2006;15:696-703.
7. Miller CS, Johnstone BM. Human papillomavirus as a risk factor for oral squamous cell carcinoma: a meta-analysis, 1982-1997. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2001;91:622-35.
8. Shiu MN, Chen TH, Chang SH, Hahn LJ. Risk factors for leukoplakia and malignant transformation to oral carcinoma: a leukoplakia cohort in Taiwan. Br J Cancer 2000;82:1871-4.
9. Trubetskoy VS, Cannillo JA, Milshtein A, Wolf GL, Torchilin VP. Controlled delivery of Gd-containing liposomes to lymph nodes: surface modification may enhance MRI contrast properties. Magn Reson Imaging 1995;13:31-7.
10. Valdes Olmos RA, Balm AJ, Hilgers FJ, Koops W, Loftus BM, Tan IB, et al. Thallium-201 SPECT in the diagnosis of head and neck cancer. J NuclMed 1997;38:873-9.
11. Buck AK, Schirrmeister H, Hetzel M, Von DerHeide M, Halter G, GlattingG, et al. 3-deoxy-3-[(18)F]fluorothymidine-positron emission tomography for noninvasive assessment of proliferation in pulmonary nodules. Cancer Res 2002;62:3331-4.
12. Rajendran JG, Mankoff DA, O'Sullivan F, Peterson LM, Schwartz DL, Conrad EU, et al. Hypoxia and glucose metabolism in malignant tumors: evaluation by [18F]fluoromisonidazole and [18F]fluorodeoxyglucose positron emission tomography imaging. Clin Cancer Res 2004;10:2245-52.
13. Van deWiele C, Lahorte C, Oyen W, Boerman O, Goethals I, Slegers G, et al. Nuclear medicine imaging to predict response to radiotherapy: a review. Int J Radiat Oncol Biol Phys 2003;55:5-15.
14. Thorek DL, Ulmert D, Diop NF, Lupu ME, Doran MG, Huang R, et al. Noninvasive mapping of deep-tissue lymph nodes in live animals using a multimodal PET/MRI nanoparticle. Nat Commun 2014;5:3097.
15. Dolmans DE, Fukumura D, Jain RK. Photodynamic therapy for cancer. Nat Rev Cancer 2003;3:380-7.
16. Lovell JF, Liu TW, Chen J, Zheng G. Activatable photosensitizers for imaging and therapy. Chem Rev 2010;110:2839-57.
17. Jin CS, Cui L, Wang F, Chen J, Zheng G. Targeting-triggered porphysome nanostructure disruption for activatable photodynamic therapy. Adv Healthc Mater 2014;3:1240-9.
18. Dougherty TJ, Gomer CJ, Henderson BW, Jori G, Kessel D, KorbelikM, et al. Photodynamic therapy. J Natl Cancer Inst 1998;90:889-905.
19. Wilson BC, Patterson MS. The physics, biophysics and technology of photodynamic therapy. Phys Med Biol 2008;53:R61-109.
20. Cui L, Lin Q, Jin CS, Jiang W, Huang H, Ding L, et al. A PEGylation-Free Biomimetic Porphyrin Nanoplatform for Personalized Cancer Theranostics. ACS Nano 2015;9:4484-95.
21. Jin CS, Lovell JF, Chen J, Zheng G. Ablation of hypoxic tumors with doseequivalent photothermal, but not photodynamic, therapy using a nanostructured porphyrin assembly. ACS Nano 2013;7:2541-50.
22. Lovell JF, Jin CS, Huynh E, Jin H, Kim C, Rubinstein JL, et al. Porphysome nanovesicles generated by porphyrin bilayers for use as multimodal biophotonic contrast agents. Nat Mater 2011;10:324-32.
23. Li SJ, Ren GX, Jin WL, Guo W. Establishment and characterization of a rabbit oral squamous cell carcinoma cell line as a model for in vivo studies. Oral Oncol 2011;47:39-44.
24. Lin LM, Chen YK, Chen CH, Chen YW, Huang AH, Wang WC. VX2- induced rabbit buccal carcinoma: a potential cancer model for human buccal mucosa squamous cell carcinoma. Oral Oncol 2009;45:e196- 203.25.
25. Lucey BC, Stuhlfaut JW, Soto JA.Mesenteric lymph nodes seen at imaging: causes and significance. Radiographics 2005;25:351-65.
26. Pagliarulo V, Hawes D, Brands FH, Groshen S, Cai J, Stein JP, et al. Detection of occult lymph node metastases in locally advanced nodenegative prostate cancer. J Clin Oncol 2006;24:2735-42.
27. Hasegawa T, Tanakura M, Takeda D, Sakakibara A, Akashi M, Minamikawa T, et al. Risk factors associated with distant metastasis in patients with oral squamous cell carcinoma. Otolaryngol Head Neck Surg 2015;156:1053-63.
28. Pantel K, Brakenhoff RH. Dissecting the metastatic cascade. Nat Rev Cancer 2004;4:448-56.
29. Forastiere A, KochW, Trotti A, Sidransky D.Head and neck cancer.NEngl J Med 2001;345:1890-900.
30. Nieuwenhuis EJ, Castelijns JA, Pijpers R, van den Brekel MW, Brakenhoff RH, van derWaal I, et al. Wait-and-see policy for the N0 neck in early-stage oral and oropharyngeal squamous cell carcinoma using ultrasonographyguided cytology: is there a role for identification of the sentinel node? Head Neck 2002;24:282-9.
31. Leusink FK, van Es RJ, de Bree R, Baatenburg de Jong RJ, van Hooff SR, Holstege FC, et al. Novel diagnostic modalities for assessment of the clinically node-negative neck in oral squamous-cell carcinoma. Lancet Oncol 2012;13:e554-61.
32. Weiss MH, Harrison LB, Isaacs RS. Use of decision analysis in planning a management strategy for the stage N0 neck. Arch Otolaryngol Head Neck Surg 1994;120:699-702.
33. Bradley PJ, Ferlito A, Silver CE, Takes RP, Woolgar JA, Strojan P, et al. Neck treatment and shoulder morbidity: still a challenge. Head Neck 2011;33:1060-7.
34. van Wilgen CP, Dijkstra PU, van der Laan BF, Plukker JT, Roodenburg JL. Morbidity of the neck after head and neck cancer therapy. Head Neck 2004;26:785-91.
35. van Wouwe M, de Bree R, Kuik DJ, de Goede CJ, Verdonck-de Leeuw IM, Doornaert P, et al. Shoulder morbidity after non-surgical treatment of the neck. Radiother Oncol 2009;90:196-201.
36. Burcia V, Costes V, Faillie JL, Gardiner Q, de Verbizier D, Cartier C, et al. Neck restaging with sentinel node biopsy in T1-T2N0 oral and oropharyngeal cancer: Why and how? Otolaryngol Head Neck Surg 2010;142: 592-7 e1.
37. de Rosa N, Lyman GH, Silbermins D, Valsecchi ME, Pruitt SK, Tyler DM, et al. Sentinel node biopsy for head and neck melanoma: a systematic review. Otolaryngol Head Neck Surg 2011;145:375-82.
38. Koch WM, Choti MA, Civelek AC, Eisele DW, Saunders JR. Gamma probedirected biopsy of the sentinel node in oral squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 1998;124:455-9.
39. Huynh E, Zheng G. Cancer nanomedicine: addressing the dark side of the enhanced permeability and retention effect. Nanomedicine 2015;10: 1993-5.
40. Chen Y, Gryshuk A, Achilefu S, Ohulchansky T, Potter W, Zhong T, et al. A novel approach to a bifunctional photosensitizer for tumor imaging and phototherapy. Bioconjug Chem 2005;16:1264-74.